Effectiveness and safety of adjunctive cenobamate in people with focal-onset epilepsy: Interim results after 24-week observational period from the BLESS study

Objective: Cenobamate is an antiseizure medication (ASM) with a dual mecha-nism of action that was recently approved for the treatment of focal seizures inadults. This analysis aimed to describe the outcomes at 12 and 24 weeks afterstarting cenobamate therapy in a real- world setting.Methods: BLESS [NCT05859854] is an ongoing, observational, retrospective andprospective cohort study to evaluate the real-world effectiveness and safety of ad-junctive cenobamate in adults with uncontrolled focal epilepsy. Subgroup analy-sis was performed in subjects with 2 to 3 previous ASMs (early users) and thosewith >3 previous ASMs (late users).